Events | 2010.01.13
GENFIT: Potential for Combination of GFT505 with Statins
LILLE, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces the absence of a safety risk due to pharmacokinetic drug-drug interaction when GFT505 is co-administered with a statin (GFT505-1095 clinical study). These results prepare the launch of Phase IIb and
For more information, please visit
http://www.businesswire.com/news/home/20100113006198/en
